Resources

Insulin resistance and weight gain are common with PCOS and impact multiple CVD risk factors.

Changes include enhanced emphasis on the role of social and financial determinants in diabetes patient health. 

Glargine and degludec had similar glycemic control with some differences in pharmacokinetics (PK) and pharmacodynamics (PD). 

Some metabolic factors, including type 2 diabetes, can increase the risk of severe non-alcoholic fatty liver disease (NAFLD). 

As the new vaccines for COVID-19 are rolled out, the Institute for Safe Medication Practices (ISMP) has called attention to some of the missteps in vaccine administration that have occurred, and offers safe practice recommendations.

A retrospective observational study seeks to determine absolute risk of death due to CVD, cancer, and other causes in patients who experienced a severe hypoglycemic event.

A post hoc analysis of the DECLARE-TIMI 58 trial may provide a new compelling indication for dapagliflozin.

Simple add-on therapy can reduce insulin use for patients with type 2 diabetes.

Initiating the right medications upon diabetes diagnosis can help mitigate heart attack risk. 

A new study shows that a potato-based diet does not disturb blood sugar control in patients with type 2 diabetes mellitus (T2DM).